Unusual Synchronous Methimazole-Induced Agranulocytosis and Severe Hepatotoxicity in Patient with Hyperthyroidism: A Case Report and Review of the Literature.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 4427828)

Published in Int J Endocrinol on April 28, 2015

Authors

Jun Yang1, Jun Zhang1, Qin Xu1, Guo-Ping Sheng2, Wan-Wen Weng1, Meng-Jie Dong1

Author Affiliations

1: The Department of Nuclear Medicine, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
2: Collaborative Innovation Center for Diagnosis and Treatment of Infectious Disease, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.

Articles cited by this

Antithyroid drugs. N Engl J Med (2005) 7.43

Clinical practice. Graves' disease. N Engl J Med (2008) 5.78

Thyrotoxicosis. Lancet (2012) 2.22

Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl (2004) 1.96

Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol (2008) 1.69

Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab (1997) 1.68

Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem (2009) 1.50

Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid (2009) 1.48

Antithyroid drug-induced agranulocytosis: special reference to normal white blood cell count agranulocytosis. Thyroid (2004) 1.40

Methimazole-induced hepatotoxicity. Endocr Pract (2002) 1.19

Propylthiouracil-induced agranulocytosis, toxic hepatitis, and death. J Am Med Assoc (1952) 1.17

Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab (2013) 1.16

Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves' disease. J Clin Endocrinol Metab (2011) 1.09

Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity. Clin Exp Immunol (2002) 1.06

Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother (2003) 1.06

Spontaneous reporting of adverse reactions to carbimazole and propylthiouracil in the UK. Clin Endocrinol (Oxf) (2004) 1.01

Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. J Clin Endocrinol Metab (1995) 1.01

Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells. Br J Haematol (1986) 1.00

Oxidation of propylthiouracil to reactive metabolites by activated neutrophils. Implications for agranulocytosis. Drug Metab Dispos (1991) 0.93

Methimazole-induced agranulocytosis: growth inhibition of myeloid progenitor cells by the patient's serum. Eur J Haematol (1988) 0.82

Concomitant agranulocytosis and hepatotoxicity after treatment with carbimazole. Ann Pharmacother (2006) 0.81

Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment. Thyroid (2014) 0.81

Acute cholestatic hepatitis along with agranulocytosis: a rare side effect of carbimazole. Ann Afr Med (2010) 0.77

Agranulocytosis and hepatic dysfunction following propylthiouracil treatment. Aust N Z J Med (1994) 0.77